natgillin/translations-raw huggingface dataset:
Adolescents: the safety profile observed in women less than 18 years old in studies and post-marketing is similar to the safety profile in adults during the phase III program (see section 4.2). 
Mladostnice: varnostni profil pri ženskah, starih manj kot 18 let, v študijah in v obdobju trženja, je podoben varnostnemu profilu pri odraslih v III. fazi programa (glejte poglavje 4.2).
Special populations Renal impairment 
Posebne populacije Okvara ledvic
Such high doses were well-tolerated; however, these women had a shortened menstrual cycle (uterine bleeding occurring 2-3 days earlier than would be expected) and in some women, the duration of bleeding was prolonged, although not excessive in amount (spotting). 
Tako visoke odmerke so dobro prenesle; vendar pa so poročale o skrajšanem menstruacijskem ciklusu (do menstrualne krvavitve je prišlo 2-3 dni bolj zgodaj kot je bilo pričakovano), pri nekaterih ženskah pa je bilo tudi trajanje krvavitve podaljšano, ni pa bila krvavitev bolj obilna (šibka krvavitev).
E-mail: info-ella@hra-pharma.com 
E-pošta: info-ella@hra-pharma.com
In any case, women should be advised to adopt a regular method of contraception. 
Ženskam je treba v vsakem primeru svetovati uporabo redne kontracepcije.
Your doctor may prescribe another type of (non-hormonal) emergency contraceptive, i.e. a Cu-IUD. 
Vaš zdravnik vam lahko predpiše drugo vrsto (nehormonske) nujne kontracepcije, tj. Cu-IUD.
Most findings in general toxicity studies were related to its mechanism of action as a modulator of progesterone and glucocorticoid receptors, with antiprogesterone activity observed at exposures similar to therapeutic levels. 
Večina ugotovitev iz splošnih študij toksičnosti se je nanašala na mehanizem delovanja kot modulator progesteronskih in glukokortikoidnih receptorjev, pri čemer je bilo antiprogesteronsko delovanje opaženo pri izpostavljenosti, podobni terapevtskim odmerkom.
Tell your pharmacist, doctor or other healthcare professional if you are taking or have recently taken any other medicines, including medicines obtained without a prescription or herbal medicines. 
Obvestite farmacevta, zdravnika ali drugega zdravstvenega delavca, če jemljete ali ste pred kratkim jemali katero koli drugo zdravilo, vključno z zdravili, ki so na voljo brez recepta, ali zdravili rastlinskega izvora.
It should in no instance replace a regular contraceptive method. 
V nobenem primeru ne sme nadomestiti redne kontracepcije.
Limited human data regarding pregnancy exposure to ellaOne do not suggest any safety concern. 
Omejeni podatki, pridobljeni pri ljudeh glede izpostavljenosti zdravilu ellaOne med nosečnostjo, ne kažejo nobenih varnostnih zadržkov.
Emergency contraception will not affect your fertility. 
Nujna kontracepcija ne bo vplivala na vašo plodnost.
The majority of women (74.6%) in the phase III studies had their next menstrual period at the expected time or within ± 7 days, while 6.8% experienced menses more than 7 days earlier than expected and 18.5% had a delay of more than 7 days beyond the anticipated onset of menses. 
Večina žensk (74,6 %) je v študiji III. faze dobila naslednjo menstruacijo ob predvidenem času ali v obdobju ± 7 dni, 6,8 % žensk je dobilo menstruacijo več kot 7 dni pred predvidenim datumom, pri 18,5 % pa je menstruacija zamujala več kot 7 dni po predvidenem datumu.
Although no teratogenic potential has been observed, animal data are insufficient with regard to reproduction toxicity (see section 5.3). 
Čeprav niso opazili nobenega teratogenega potenciala, študije na živalih niso zadostne za oceno vpliva na sposobnost razmnoževanja (glejte poglavje 5.3).
Emergency contraception does not protect against sexually transmitted infections 
Nujna kontracepcija ne ščiti pred spolno prenosljivimi okužbami.
If you have used certain other medicines in the last 4 weeks, in particular for epilepsy, tuberculosis, HIV infection or herbal medicines containing St. John´s wort (see leaflet), ellaOne may work less effectively. 
Če ste v zadnjih 4 tednih jemali določena druga zdravila, zlasti za zdravljenje epilepsije, tuberkuloze, za zdravljenje okužbe z virusom HIV ali zdravila rastlinskega izvora, ki vsebujejo šentjanževko (glejte navodilo), je lahko zdravilo ellaOne manj učinkovito.
If you become pregnant despite taking this medicine, there is no evidence that it will affect your pregnancy. 
Če zanosite kljub uporabi tega zdravila, ni dokazov, da bo zdravilo vplivalo na nosečnost.
If vomiting occurs within 3 hours of the tablet intake, another tablet should be taken. 
Če se v 3 urah po zaužitju tablete pojavi bruhanje, je treba vzeti še eno tableto.
After taking this medicine, some women experience dizziness, drowsiness, blurred vision and/or loss of concentration (see section 4). 
Po uporabi tega zdravila se pri nekaterih ženskah pojavijo omotica, zaspanost, zamegljen vid in/ali poslabšanje koncentracije (glejte poglavje 4).
ellaOne does not work if you are already pregnant. 
Zdravilo ellaOne ne deluje, če ste že noseči.
Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicinal product. 
Ženske z redko dedno intoleranco za galaktozo, laponsko obliko zmanjšane aktivnosti laktaze ali malabsorpcijo glukoze/galaktoze ne smejo jemati tega zdravila.
Influenza 
- gripa
USEFUL INFORMATION ABOUT CONTRACEPTION MORE ABOUT EMERGENCY CONTRACEPTION 
UPORABNE INFORMACIJE O KONTRACEPCIJI VEČ O NUJNI KONTRACEPCIJI
This is especially important if you have severe abdominal (stomach) pain or bleeding or if you have previously had a pregnancy outside the womb, tubal surgery or long term (chronic) genital infection. 
To je še posebej pomembno, če imate hude bolečine v trebuhu ali krvavitev ali če ste v preteklosti že imeli zunajmaternično nosečnost, operacijo jajcevodov ali dolgotrajno (kronično) okužbo spolovil.
Some symptoms such as breast tenderness and abdominal (stomach) pain, throwing up (vomiting), feeling sick (nausea) are also possible signs of pregnancy. 
Nekateri simptomi, kot so občutljive dojke in bolečine v trebuhu, bruhanje, slabost s siljenjem na bruhanje (navzea), so tudi možni znaki nosečnosti.
After taking the tablet, it is normal for your next period to be a few days late. 
Po jemanju tablete je normalno, če naslednja menstruacija nastopi nekaj dni prepozno.
In the absence of specific studies, ulipristal acetate is not recommended. 
Zaradi pomanjkanja specifičnih študij se uporaba ulipristalacetata ne priporoča.
When used for emergency contraception the mechanism of action is inhibition or delay of ovulation via suppression of the luteinising hormone (LH) surge. 
Kadar se uporablja za nujno kontracepcijo, je mehanizem delovanja zaviranje ali odlaganje ovulacije, ki poteka prek zaviranja zvišanja ravni luteinizirajočega hormona (LH).
Emergency contraception can delay ovulation within a given menstrual cycle, but it will not stop you from becoming pregnant if you have unprotected sex again. 
Nujna kontracepcija lahko odloži ovulacijo v danem menstrualnem ciklusu, vendar ne bo preprečila zanositve, če boste ponovno imeli nezaščiten spolni odnos.
During this time it is recommended to express and discard the breast milk in order to stimulate lactation. 
V tem času je priporočljivo materino mleko iztisniti in zavreči, da se tako stimulira laktacija.
If you are already pregnant it will not interrupt an existing pregnancy. 
Če ste že noseči, ne bo prekinilo obstoječe nosečnosti.
Speak to your doctor or pharmacist before using ellaOne when you use (or have recently used) any of the medicines stated above. 
Pogovorite se s svojim zdravnikom ali farmacevtom preden uporabite zdravilo ellaOne, če uporabljate (ali ste pred kratkim uporabljali) katero izmed zgoraj naštetih zdravil.
P-glycoprotein (P-gp) substrates 
Substrati P-glikoproteina (P-gp)
Similar results were obtained for the active mono-demethylated metabolite. 
Podobni rezultati so bili pridobljeni tudi za aktivni monodemetilirani presnovek.
Adverse reactions listed below are classified according to frequency and system organ class using the following convention: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000) and not known (cannot be estimated from the available data). 
Spodaj našteti neželeni učinki so razvrščeni glede na pogostnost in organske sisteme v naslednji obliki: zelo pogosti (≥ 1/10), pogosti (od ≥ 1/100 do < 1/10), občasni (od ≥ 1/1.000 do < 1/100), redki (od ≥ 1/10.000 do < 1/1.000) in neznana (ni mogoče oceniti iz razpoložljivih podatkov).
Potential for ulipristal acetate to affect other medicinal products 
Možnost vpliva ulipristalacetata na druga zdravila
For the full list of excipients, see section 6.1 
Za celoten seznam pomožnih snovi glejte poglavje 6.1.
Excipients with known effect Each tablet contains 237 mg of lactose (as monohydrate). 
Pomožne snovi z znanim učinkom Ena tableta vsebuje 237 mg laktoze (monohidrat).
As for any pregnancy, your doctor may want to check that the pregnancy is not outside the womb. 
Kot pri vsaki nosečnosti bo zdravnik morda želel preveriti, ali je nosečnost zunajmaternična.
In case the next menstrual period is more than 7 days late, if the menstrual period is abnormal in character or if there are symptoms suggestive of pregnancy or in case of doubt, a pregnancy test should be performed. 
Če naslednja menstruacija zamuja več kot 7 dni, če je menstruacija nenormalnega značaja, če se pojavijo simptomi, ki kažejo na nosečnost, ali v primeru dvoma je treba opraviti test nosečnosti.
Although the use of ulipristal acetate for emergency contraception does not contraindicate the continued use of regular hormonal contraception, ellaOne may reduce its contraceptive action (see section 4.5). 
Čeprav uporaba ulipristalacetata za nujno kontracepcijo ne kontraindicira nadaljnje uporabe redne hormonske kontracepcije, lahko zdravilo ellaOne zmanjša njeno kontracepcijsko delovanje (glejte poglavje 4.5).
A minority (8.7%) of women reported intermenstrual bleeding lasting an average of 2.4 days. 
Pri manjšemu deležu žensk (8,7 %) se je v času med dvema menstruacijama pojavila krvavitev, ki je trajala povprečno 2,4 dneva.
In vitro data indicate that ulipristal acetate and its active metabolite do not significantly inhibit CYP1A2, 2A6, 2C9, 2C19, 2D6, 2E1, and 3A4, at clinically relevant concentrations. 
Podatki in vitro kažejo, da ulipristalacetat in njegov aktivni presnovek v klinično pomembnih koncentracijah nista pomembna zaviralca encimov CYP1A2, 2A6, 2C9, 2C19, 2D6, 2E1 in 3A4.
The mono-demethylated metabolite is pharmacologically active. 
Monodemetiliran presnovek je farmakološko aktiven.
If you take more ellaOne than you should 
Če ste vzeli večji odmerek zdravila ellaOne, kot bi smeli
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 
Preobčutljivost na učinkovino ali katero koli pomožno snov, navedeno v poglavju 6.1.
Normal 
Normalen
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder 
Za vse morebitne nadaljnje informacije o tem zdravilu se lahko obrnete na predstavništvo imetnika dovoljenja za promet z zdravilom:
The clinical relevance of this interaction for single dose administration of ulipristal acetate as emergency contraception is not known. 
Klinični pomen tega medsebojnega delovanja pri uporabi enega odmerka ulipristalacetata kot nujne kontracepcije ni znan.
This medicine is a contraceptive used to prevent a pregnancy from starting. 
To zdravilo je kontracepcijsko sredstvo, ki se uporablja za preprečitev nastopa nosečnosti.
For women who have used enzyme-inducing drugs in the past 4 weeks, ellaOne is not recommended (see section 4.4) and non-hormonal emergency contraception (i.e. a copper intrauterine device (Cu-IUD)) should be considered. 
Pri ženskah, ki so v zadnjih 4 tednih uporabljale zdravila, ki inducirajo encime, uporaba zdravila ellaOne ni priporočljiva (glejte poglavje 4.4), hkrati pa je treba razmisliti o nehormonski nujni kontracepciji (tj. bakrenem materničnem vložku (Cu-IUD)).
This medicine does not require any special storage conditions. 
Za to zdravilo ne veljajo posebni pogoji shranjevanja.
If you have been told by your doctor or other healthcare professional that you have an intolerance to some sugars, tell your pharmacist before taking this medicine. 
Če vam je zdravnik ali drug zdravstveni delavec povedal, da ne prenašate nekaterih sladkorjev, se pred uporabo tega zdravila posvetujte s farmacevtom.
This medicine will not protect you against HIV infection or any other sexually transmitted diseases (e.g. chlamydia, genital herpes, genital warts, gonorrhoea, hepatitis B and syphilis). 
To zdravilo vas ne bo zaščitilo pred okužbo z virusom HIV ali drugimi spolno prenosljivimi boleznimi (kot so klamidija, genitalni herpes, genitalne bradavice, gonoreja, hepatitis B in sifilis).
Therefore, if a woman wishes to start or continue using hormonal contraception, she can do so after using ellaOne, however, she should be advised to use a reliable barrier method until the next menstrual period. 
Torej, če želi ženska začeti ali nadaljevati uporabo hormonske kontracepcije, to lahko stori po uporabi zdravila ellaOne, vendar ji je treba svetovati, naj do naslednje menstruacije uporablja zanesljivo pregradno metodo.
Contents of the pack and other information What ellaOne contains 
Vsebina pakiranja in dodatne informacije Kaj vsebuje zdravilo ellaOne
Take the tablet without delay. 
Ne odlašajte z zaužitjem tablete.
In an open-label clinical trial, which enrolled women who presented for emergency contraception and were treated with ulipristal acetate between 48 and 120 hours after unprotected intercourse, a pregnancy rate of 2.1% (26/1241) was observed. 
V odprtem kliničnem preskušanju, v katerem so sodelovale ženske, ki so potrebovale nujno kontracepcijo ter so prejele ulipristalacetat v času od 48 do 120 ur po nezaščitenem spolnem odnosu ali neučinkoviti kontracepciji, je bil odstotek nosečnosti 2,1 % (26/1241).
Pregnancy ellaOne is not intended for use during pregnancy and should not be taken by any woman suspected or known to be pregnant (see section 4.2). 
Zdravilo ellaOne ni namenjeno uporabi med nosečnostjo in ga ne sme vzeti nobena ženska, ki sumi ali ve, da je noseča (glejte poglavje 4.3).
You should take the tablet as soon as possible after sex, and within a maximum of 5 days (120 hours). 
Tableto morate vzeti čim prej po spolnem odnosu in najpozneje po 5 dneh (120 urah).
Unprotected sex at any time during your cycle can lead to pregnancy. 
Nezaščiten spolni odnos kadar koli med menstrualnim ciklusom lahko privede do nosečnosti.
Ulipristal acetate is an emergency contraceptive that decreases pregnancy risk after unprotected intercourse but does not confer contraceptive protection for subsequent acts of intercourse. 
Ulipristalacetat je nujno kontracepcijsko sredstvo, ki zmanjšuje tveganje za nosečnost po nezaščitenem spolnem odnosu, vendar ne zagotavlja kontracepcijske zaščite za nadaljnje spolne odnose.
No pharmacokinetic studies with ulipristal acetate have been performed in females with impaired renal or hepatic function. 
Farmakokinetičnih študij z ulipristalacetatom pri ženskah z oslabljeno ledvično ali jetrno funkcijo niso izvedli.
ellaOne is not to be used for regular contraception 
Zdravilo ellaOne se ne sme uporabljati kot redna kontracepcijska metoda.
Ulipristal acetate is highly bound (>98%) to plasma proteins, including albumin, alpha-l-acid glycoprotein, and high density lipoprotein. 
Ulipristalacetat se močno veže (> 98 %) na plazemske beljakovine, vključno z albumini, alfa-1glikoproteini in lipoproteini visoke gostote.
Limited and inconclusive data suggest that there may be reduced efficacy of ellaOne with increasing body weight or body mass index (BMI) (see section 5.1). 
Omejeni in nedokončni podatki kažejo, da se lahko učinkovitost zdravila ellaOne manjša z večanjem telesne mase ali indeksa telesne mase (ITM) (glejte poglavje 5.1).
Ulipristal acetate is not intended for use during pregnancy and should not be taken by any woman suspected or known to be pregnant. 
Ulipristalacetat ni namenjen za uporabo med nosečnostjo in ga ne sme vzeti nobena ženska, ki sumi ali ve, da je noseča.
In all women, emergency contraception should be taken as soon as possible after unprotected intercourse, regardless of the woman's body weight or BMI. 
Pri vseh ženskah je treba nujno kontracepcijo vzeti čim prej po nezaščitenem spolnem odnosu, ne glede na telesno maso ali ITM ženske.
Limited and inconclusive data from clinical trials suggest a possible trend for a reduced contraceptive efficacy of ulipristal acetate with high body weight or BMI (see section 4.4). 
Omejeni in nedokončni podatki iz kliničnih preskušanj kažejo morebiten trend za zmanjšano učinkovitost kontracepcije ulipristalacetata pri veliki telesni masi ali ITM (glejte poglavje 4.4).
There were no safety differences in these subjects in terms of incidence and severity of adverse reactions, change in duration or volume of menses or incidence of intermenstrual bleeding. 
Med temi ženskami niso bile opažene razlike v varnosti zdravila glede incidence in resnosti neželenih reakcij, sprememb v trajanju menstruacije ali količini menstrualne krvi ali glede incidence krvavitev v času med dvema menstruacijama.
The CYP3A4 inhibitor ritonavir can also have an inducing effect on CYP3A4 when ritonavir is used for a longer period. 
Zaviralec CYP3A4, ritonavir, ima lahko prav tako inducirajoče učinke na CYP3A4, če je njegova uporaba dolgotrajna.
Laboratorios León Farma S.A. C/ La Vallina, s/n Pol. Ind. Navatejera 24008 Navatejera, León Spain 
C/ La Vallina, s/n Pol. Ind. Navatejera 24008 Navatejera, León
In all women, emergency contraception should be taken as soon as possible after unprotected intercourse. 
Pri vseh ženskah je treba nujno kontracepcijo uporabiti čim prej po nezaščitenem spolnem odnosu.
Take one tablet as soon as possible after unprotected sex or contraceptive failure. 
Vzemite eno tableto čim prej po nezaščitenem spolnem odnosu ali neučinkoviti kontracepciji.
Emergency contraception 
Nujna kontracepcija
In 18.5% of the women a delay of more than 7 days occurred, and in 4% the delay was greater than 20 days. 
Pri približno 18,5% žensk je menstruacijski ciklus zamujal več kot 7 dni, pri 4 % žensk pa je bila zamuda daljša od 20 dni.
Women should be advised to use a reliable barrier method for all subsequent acts of intercourse until the next menstrual period. 
Ženskam je treba svetovati, naj do naslednje menstruacije uporabljajo zanesljivo pregradno metodo za vse nadaljnje spolne odnose.
This medicine may make regular hormonal contraceptives, like pills and patches, temporarily less effective. 
Druga kontracepcijska sredstva in zdravilo ellaOne Zaradi tega zdravila je lahko redna hormonska kontracepcija, kot so tablete in obliži, začasno manj učinkovita.
Women who become pregnant after taking ulipristal acetate should contact their doctor (see section 4.6). 
Ženske, ki zanosijo po jemanju ulipristalacetata, se morajo posvetovati z zdravnikom (glejte poglavje 4.6).
Before taking this medicine, if your period is late, tell your pharmacist, doctor or other healthcare professional, or do a pregnancy test in order to make sure you are not already pregnant (see section “Warning and precautions”). 
Pred jemanjem tega zdravila ali če vam menstruacija zamuja, o tem obvestite farmacevta, zdravnika ali drugega zdravstvenega delavca ali pa opravite test nosečnosti, da se prepričate, da niste že noseči (glejte poglavje »Opozorila in previdnostni ukrepi«).
The meta-analysis of the four clinical studies conducted with ulipristral acetate presented below excluded women who had further acts of unprotected intercourse. 
Pri spodaj predstavljeni metaanalizi štirih kliničnih študij z ulipristilacetatom so izključili ženske, ki so nadaljevale z nezaščitenimi spolnimi odnosi.
Pharmacodynamic data show that even when taken immediately before ovulation is scheduled to occur (when LH has already started to rise), ulipristal acetate is able to postpone follicular rupture for at least 5 days in 78.6% of cases (p<0.005 vs. levonorgestrel and vs. placebo) 
Farmakodinamični podatki kažejo, da je ulipristalacetat, tudi če se vzame tik pred predvideno ovulacijo (ko je raven LH že začela naraščati), v 78,6 % primerov zmožen odložiti razpok folikla za vsaj 5 dni (p < 0,005 v primerjavi z levonorgestrelom in placebom) (glejte preglednico).
The terminal half-life of ulipristal acetate in plasma following a single 30 mg dose is estimated to 32.4 ± 6.3 hours, with a mean oral clearance (CL/F) of 76.8 ± 64.0 L/h. 
Končni razpolovni čas ulipristalacetata v plazmi po enkratnem 30-miligramskem odmerku je ocenjen na 32,4 ± 6,3 ure, s povprečnim peroralnim očistkom (CL/F) 76,8 ± 64,0 l/h.
Visual disturbance Abnormal sensation in eye Ocular hyperaemia 
Očesne bolezni motnje vida nenormalen občutek v očesu očesna hiperemija fotofobija
In vitro data indicate that this is predominantly mediated by CYP3A4, and to a small extent by CYP1A2 and CYP2A6. 
Podatki študij in vitro kažejo, da pri tem večinoma sodeluje CYP3A4, manj pa CYP1A2 in CYP2A6CYP2A6.
Contents of the pack and other information - Useful information about contraception 
Shranjevanje zdravila ellaOne Vsebina pakiranja in dodatne informacije - Uporabne informacije o kontracepciji
See leaflet for further information. 
Za več informacij glejte priloženo navodilo.
After intake of ulipristal acetate for emergency contraception, breast-feeding is not recommended for one week. 
Po vnosu ulipristalacetata za nujno kontracepcijo se dojenje odsvetuje en teden.
Results in vivo with the P-gp substrate fexofenadine were inconclusive. 
Rezultati in vivo s substratom P-gp, feksofenadinom, niso bili dokončni.
Do not take ellaOne together with another emergency contraceptive pill that contains levonorgestrel. 
Zdravila ellaOne ne jemljite skupaj z drugimi nujnimi kontracepcijskimi tabletami, ki vsebujejo levonorgestrel.
Golden film-coated tablet of shield shape (around 10,8 mm diameter) with “ella” engraved on both sides. 
Filmsko obložena tableta zlate barve v obliki ščita (približnega premera 10,8 mm) z vtisnjenim napisom “ella” na obeh straneh.
Pregnancy rate (%) within 72h of unprotected intercourse or contraceptive failure2 
Razmerje nosečnosti (%) v roku 72 ur po nezaščitenem spolnem odnosu ali neučinkoviti kontracepciji2
When your period is late or when you have symptoms of pregnancy (heavy breasts, morning sickness) you should consult a doctor or other healthcare professional before taking the tablet. 
Če vam menstruacija zamuja ali če imate simptome nosečnosti (težke prsi, jutranja slabost), se pred jemanjem tablete posvetujte z zdravnikom ali drugim zdravstvenim delavcem.
See section “Pregnancy, breast-feeding and fertility” for more information. 
Za več informacij glejte poglavje »Nosečnost, dojenje in plodnost«.
- CYP3A4 inhibitors 
− Zaviralci CYP3A4
Ulipristal acetate is an orally-active synthetic selective progesterone receptor modulator which acts via high-affinity binding to the human progesterone receptor. 
Ulipristalacetat je peroralno aktivni selektivni sintetični modulator progesteronskih receptorjev, ki se v človeškem organizmu z visoko afiniteto veže na progesteronske receptorje.
- if you are allergic to ulipristal acetate or any of the other ingredients of this medicine (listed in section 6). 
Ne jemljite zdravila ellaOne - če ste alergični na ulipristalacetat ali katero koli sestavino tega zdravila (navedeno v poglavju 6).
Do not take this medicine together with another emergency contraceptive pill that contains levonorgestrel. 
Tega zdravila ne jemljite skupaj z drugimi nujnimi kontracepcijskimi tabletami, ki vsebujejo levonorgestrel.
If a woman's menstrual period is late or in case of symptoms of pregnancy, pregnancy should be excluded before the tablet is administered. 
Če ženski zamuja menstruacija ali se pojavijo znaki nosečnosti, je treba izključiti nosečnost, preden ženska vzame tableto.